Mortality in HIV-Seropositive versus -Seronegative Persons in the Era of Highly Active Antiretroviral Therapy: Implications for When to Initiate Therapy

Background. The optimal time to initiate highly active antiretroviral therapy (HAART) remains unclear. Methods. Five hundred eighty-three human immunodeficiency virus (HIV)-seropositive and 920 HIV-seronegative injection drug users (IDUs) were followed from 1997 to 2000. HIV-seropositive participant...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Journal of infectious diseases 2004-09, Vol.190 (6), p.1046-1054
Hauptverfasser:	Wang, Cunlin, Vlahov, David, Galai, Noya, Bareta, Joseph, Strathdee, Steffanie A., Nelson, Kenrad E., Sterling, Timothy R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult AIDS Anti-HIV Agents - therapeutic use Antiretroviral Therapy, Highly Active Antiretrovirals Antivirals Cause of Death Causes of death CD4 Lymphocyte Count Death Disease progression Female Follow-Up Studies Highly active antiretroviral therapy HIV HIV Infections - complications HIV Infections - drug therapy HIV Infections - immunology HIV Infections - mortality HIV Seronegativity HIV Seropositivity HIV/AIDS Human immunodeficiency virus Humans Injections Male Middle Aged Mortality Proportional Hazards Models Substance Abuse, Intravenous - complications Substance Abuse, Intravenous - mortality Survival Analysis Time Factors Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!